Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.55 |
| ▸ | BCHE | P06276 | 5/20 | 0.55 |
| ▸ | ACHE | P22303 | 5/20 | 0.55 |
| ▸ | BACE1 | P56817 | 4/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5205810 | 1.00 | ROCK1 (0.56) | ROCK1ROCK2CCR2BCHEACHE | |
| SCHEMBL3546613 | 0.93 | ACHE (0.60) | BCHEACHEBACE1FAAH | |
| SCHEMBL27720300 | 0.89 | HRH3 (0.54) | KCNH2 | |
| SCHEMBL3545728 | 0.85 | HRH3 (0.62) | BCHEACHEBACE1FAAH | |
| SCHEMBL9598403 | 0.85 | ROCK1 (0.65) | ROCK1ROCK2CCR2BCHEKCNH2 | |
| SCHEMBL6181435 | 0.83 | ALDH1A1 (0.49) | ACHEKCNH2 | |
| SCHEMBL9235807 | 0.82 | HRH3 (0.61) | KCNH2 | |
| SCHEMBL11729293 | 0.82 | ROCK1 (0.61) | ROCK1ROCK2CCR2BCHEKCNH2 | |
| SCHEMBL27573482 | 0.81 | MGLL (0.48) | CCR2BCHEACHEBACE1 | |
| SCHEMBL12478315 | 0.81 | CCR2 (0.52) | ROCK1ROCK2CCR2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790751-B2 | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1915348-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth a Corporation of the State of Delaware (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007032833-A1 | AZINYL-3-SULFONYLINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2007-03-22 | — | — | WO | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | WYETH (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054896-A1 | Serotonin (5-HT6) receptor ligands such as 3-(1-naphthylsulfonyl)-5-(piperidin-4-yloxy)-1H-indazole, used for the treatment nervous sytem disorders such as attention deficit disorder, anxiety, epilepsy, depression, schizophrenia, obsessive compulsive, sleep, eating and neurodegenerative disorders | HTR6, HTR1A, HTR3B | ROCK1 2432/4885ROCK2 2526/4885CCR2 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.